MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

Search

Ipsen SA.

Open

SectorFinance

97.45 0.98

Overview

Share price change

24h

Current

Min

96.05

Max

98.5

Key metrics

By Trading Economics

Income

-118M

114M

Sales

71M

1.8B

P/E

Sector Avg

21.241

20.525

Dividend yield

1.54

Profit margin

6.249

Employees

5,358

EBITDA

228M

710M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+26.45% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.54%

4.36%

Market Stats

By TradingEconomics

Market Cap

7.5B

Previous open

96.47

Previous close

97.45

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Ipsen SA. Chart

Past performance is not a reliable indicator of future results.

Related News

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Ipsen SA. Forecast

Price Target

By TipRanks

26.45% upside

12 Months Forecast

Average 119.75 EUR  26.45%

High 145 EUR

Low 100 EUR

Based on 8 Wall Street analysts offering 12 month price targets forIpsen SA. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

3

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

94.4 / 97.4Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.